AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

We launched AdCella, our "east to west" cellular immunotherapy strategy with partnerships with SYNthesis BioVentures and Cell Therapies Pty Ltd. We are conducting diligence on more than 10 assets to build our clinical pipeline beyond AD-214

We built further momentum towards partnerships in our AdSolis business unit that will support Phase II clinical studies of AD-214. This included unexpected, but very positive, new approaches at BIO24 from newly formed, venture backed companies seeking to license or acquire assets like AD-214

We raised $3.1m from institutional investors and large existing shareholders, with additional funds available as required

Quarterly Appendix 4C and Activities Report

Summary